DK0880363T3 - Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger - Google Patents

Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger

Info

Publication number
DK0880363T3
DK0880363T3 DK97907545T DK97907545T DK0880363T3 DK 0880363 T3 DK0880363 T3 DK 0880363T3 DK 97907545 T DK97907545 T DK 97907545T DK 97907545 T DK97907545 T DK 97907545T DK 0880363 T3 DK0880363 T3 DK 0880363T3
Authority
DK
Denmark
Prior art keywords
inhibitor
leukotriene
cyclooxygenase
combinations
well
Prior art date
Application number
DK97907545T
Other languages
Danish (da)
English (en)
Inventor
Susan A Gregory
Peter C Isakson
Gary Anderson
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0880363T3 publication Critical patent/DK0880363T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97907545T 1996-02-13 1997-02-11 Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger DK0880363T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60065596A 1996-02-13 1996-02-13
PCT/US1997/001421 WO1997029774A1 (en) 1996-02-13 1997-02-11 Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor

Publications (1)

Publication Number Publication Date
DK0880363T3 true DK0880363T3 (da) 2003-01-20

Family

ID=24404526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907545T DK0880363T3 (da) 1996-02-13 1997-02-11 Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger

Country Status (11)

Country Link
US (3) US6407140B1 (enExample)
EP (1) EP0880363B1 (enExample)
JP (1) JP2001506574A (enExample)
AT (1) ATE223732T1 (enExample)
AU (1) AU1952597A (enExample)
CA (1) CA2246336A1 (enExample)
DE (1) DE69715382T2 (enExample)
DK (1) DK0880363T3 (enExample)
ES (1) ES2183140T3 (enExample)
PT (1) PT880363E (enExample)
WO (1) WO1997029774A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69709069T2 (de) * 1996-02-13 2002-07-04 G.D. Searle & Co., Chicago Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
NZ524252A (en) 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
KR20050034603A (ko) 2001-10-09 2005-04-14 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 디페닐옥사졸, 이의 합성 및 이의 형광프로브로서의 용도
WO2004019891A2 (en) * 2002-08-28 2004-03-11 Sangstat Medical Corporation Methods and compostions for immune tolerance
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
EP1976828B1 (en) * 2005-12-29 2016-12-21 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
PA8802501A1 (es) * 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
CA2721099C (en) 2008-04-11 2017-04-25 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
NZ596137A (en) 2009-05-14 2013-08-30 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
CA2906086A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
EP4360632B1 (en) 2019-01-15 2025-10-29 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5242940A (en) 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
GB8927287D0 (en) 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5220059A (en) 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
AU647177B2 (en) 1990-07-25 1994-03-17 Abbott Laboratories Acetylenic urea derivatives having lipoxygenase inhibitory activity
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
CA2365269A1 (en) 1991-01-31 1992-08-20 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (en) 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
RO118291B1 (ro) 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
EP1640003A2 (en) * 1996-02-13 2006-03-29 G.D. SEARLE & CO. Compositions comprising a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 receptor antagonist

Also Published As

Publication number Publication date
DE69715382D1 (de) 2002-10-17
DE69715382T2 (de) 2003-04-30
JP2001506574A (ja) 2001-05-22
PT880363E (pt) 2002-12-31
US20030004191A1 (en) 2003-01-02
US6407140B1 (en) 2002-06-18
WO1997029774A1 (en) 1997-08-21
EP0880363A1 (en) 1998-12-02
EP0880363B1 (en) 2002-09-11
US20050043355A1 (en) 2005-02-24
ATE223732T1 (de) 2002-09-15
ES2183140T3 (es) 2003-03-16
AU1952597A (en) 1997-09-02
CA2246336A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
AU1952597A (en) Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
WO2001084376A3 (en) System for answering natural language questions
DK1066052T3 (da) Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
AU2821601A (en) Multipotent neural stem cells from peripheral tissues and uses thereof
DE69737724D1 (de) Genidentifikationsverfahren
AU3869501A (en) Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
WO2004050826A3 (en) Method of dynamically culturing embryonic stem cells
DE3865044D1 (de) Mittelohr-prothese.
GB2370969A (en) Insect trap
AU1850597A (en) Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
DK1161521T3 (da) Transplantation af hæmatopoietiske celler
DE60042209D1 (de) Enzymatische synthese von deoxyribonucleotiden
WO2007062387A3 (en) Hair grafts derived from plucked hair
Lovejoy Satanizing the American Indian
BR9609113A (pt) Composição para prevenção e/ou remoção de biopelícula em superfícies e uso da composiç o
ES2175116T3 (es) Metodos para determinar el genotipo del color del pelaje de un cerdo.
WO2021207207A3 (en) De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
ES2165551T3 (es) Bacillus sp. ac13 alcalofilo y xilanasa obtenida a partir de dicha especie.
Thipa The difference between rural and urban Xhosa varieties: A sociolinguistic study.
Garr A Note on the Pluractional Piel
Ruse Biological adaptation
SE9603335D0 (sv) Leksak
Goto et al. Corrigendum: Esmaeilzadeh-Salestani K, Queiroz MB, Mikryukov V, Uszok S, Goto BT, Tedersoo L, Magurno F (2025) Morphological and phylogenetic analysis of the early-diverging lineage of Glomeromycota suggest two new genera and recombinations in Archaeosporales. MycoKeys 124: 249-273. https://doi. org/10.3897/mycokeys. 124.166449
Magurno Bruno Tomio Goto, Mariana Bessa de Queiroz 2, Keyvan Esmaeilzadeh-Salestani3, 4, Vladimir Mikryukov3, 5, Sylwia Uszok 6, Leho Tedersoo3, 7, Franco Magurno 6
Schuurman et al. Interview: Madagascar’s rosewood stocks–which way to go?